Rocatinlimab: The OX40 Eczema Antibody That Won Its Trials but Lost Its Future (September 26, 2026)
Table of Contents
What rocatinlimab is, in one line
Rocatinlimab (development codes AMG 451 and KHK4083) is an investigational antibody developed by Kyowa Kirin and Amgen for moderate-to-severe atopic dermatitis (eczema). Instead of blocking a single itch-and-inflammation messenger, it targets OX40 - a receptor on activated T cells - and actually reduces the pathogenic T cells that keep eczema smoldering. It was given by subcutaneous injection, reached late-stage (Phase 3) testing, was never approved, and its development was discontinued in 2026.
Why OX40 - and why the receptor-versus-ligand choice matters
OX40 (on T cells) and its partner OX40L (on antigen-presenting cells) form a costimulatory 'second signal' that keeps effector and memory T cells switched on. That axis helps drive the chronic, relapsing inflammation of atopic dermatitis. There are two ways to hit it. You can block the ligand and simply mute the signal - that is amlitelimab, a non-depleting approach. Or you can target the receptor on the T cells and delete the cells carrying it - that is rocatinlimab, which its makers branded a 'T-cell rebalancing' therapy. The receptor-depleting design was the whole point: prune the pathogenic memory T cells that fuel flares and you might get deep, potentially durable, even off-drug disease control - true disease modification rather than continuous suppression.
The Phase 3 ROCKET data, in plain numbers
The pivotal program (ROCKET) was unusually large - eight studies. In ROCKET-IGNITE (NCT05398445), a 24-week trial in 769 adults using rocatinlimab on top of topical therapy, the drug met both co-primary endpoints: at week 24, EASI-75 (75% skin-severity improvement) reached about 42% on the higher dose and 36% on the lower dose versus roughly 13% on placebo, and vIGA-AD 0/1 (clear/almost-clear skin) about 24% and 19% versus placebo. In the monotherapy study ROCKET-HORIZON (NCT05651711), EASI-75 hit about 33% versus 14% on placebo, and vIGA-AD 0/1 about 19% versus 7%. The pooled results were published in The Lancet in 2025, and a long-term extension (ROCKET-ASCEND) reported top-line data in September 2025. On paper, this was a win.
The first crack: efficacy without differentiation
The problem is that beating placebo is not the same as beating the competition. In ROCKET-HORIZON, rocatinlimab did not show superiority over dupilumab, the market-leading eczema biologic, and its response rates were more modest than some rivals. The tolerability profile did not help: the most common adverse events were pyrexia (fever), chills, headache and mouth/aphthous ulcers, reflecting the antibody's habit of briefly activating T cells before depleting them. A drug that works but does not clearly out-perform an entrenched standard is a hard commercial sell - and that showed up in the boardroom before it showed up in the clinic.
The collapse: Amgen exits, then Kaposi's sarcoma ends it
In January 2026, Amgen announced it was ending the rocatinlimab collaboration, citing strategic portfolio prioritization, and returned global rights to Kyowa Kirin, which said it would take full control and file for approval in the first half of 2026. That plan lasted weeks. On March 3, 2026, Kyowa Kirin announced the discontinuation of ALL rocatinlimab clinical trials - across atopic dermatitis, prurigo nodularis and uncontrolled asthma - after a safety review identified cases of Kaposi's sarcoma: one newly confirmed and one suspected, in addition to a previously confirmed case. The company said these suggested a possible mechanistic link to OX40-pathway modulation that could not be excluded, even though the cases were rare. Patients were allowed to complete safety follow-up before the studies were formally closed.
What it means for the whole OX40 field
Rocatinlimab's downfall reframed a live scientific debate. Its mechanism depletes OX40-bearing T cells, and one hypothesis is that removing those cells impairs the immune surveillance that normally keeps Kaposi's-sarcoma-associated herpesvirus in check. The natural comparison is amlitelimab, which blocks the OX40 ligand without depleting cells and reported only a single Kaposi's sarcoma case while continuing toward regulatory submission. So is the malignancy risk specific to depleting the OX40 receptor, or is it a class-wide concern for anything that touches the OX40 axis? Nobody knows yet - and that question now hangs over every OX40-targeting program, including the anti-OX40 receptor peer telazorlimab.
The bottom line
Rocatinlimab is a rare case of a drug that met its Phase 3 endpoints, got into The Lancet, and still ended up shelved - undone first by failing to differentiate from dupilumab and then, decisively, by a malignancy safety signal that stopped the entire program in 2026. It is a genuinely important compound to understand precisely because it did not work out: it is a clean test of the risks of T-cell-depleting immunotherapy and a pivotal data point in the OX40-receptor-versus-OX40-ligand story. But as a therapy it is investigational, was never approved anywhere, and is no longer in development. Anything sold as 'rocatinlimab', 'AMG 451' or 'KHK4083' outside a clinical trial is unverified and should not be used.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials - The Lancet (2025) Source
- [2] Amgen and Kyowa Kirin Provide Top-Line Results From Rocatinlimab Phase 3 IGNITE Study in Adults With Moderate to Severe Atopic Dermatitis (March 2025) - Amgen Source
- [3] Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis (September 2025) - Amgen Source
- [4] Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization (January 30, 2026) - Kyowa Kirin Source
- [5] Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials (March 3, 2026) - Kyowa Kirin Source
- [6] Kyowa Kirin abandons touted eczema drug following safety review (2026) - BioPharma Dive Source
- [7] A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) - ClinicalTrials.gov NCT05398445 Source
- [8] ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis - Immunotherapy (2025) Source
Related Articles
Depemokimab (Exdensur): The First Twice-Yearly Anti-IL-5 Biologic for Severe Eosinophilic Asthma (September 17, 2026)
Depemokimab (Exdensur, depemokimab-ulaa) is the first ultra-long-acting anti-IL-5 antibody - engineered to be injected just twice a year. By neutralizing interleukin-5, the master cytokine for eosinophils, it curbs the type 2 inflammation behind severe eosinophilic asthma. In the pivotal Phase 3 SWIFT-1 and SWIFT-2 trials it roughly halved asthma exacerbations and cut hospitalization-level flares by about 72%, earning FDA approval in December 2025 as a twice-yearly add-on maintenance therapy for severe asthma with an eosinophilic phenotype.
Barzolvolimab (CDX-0159): A First-in-Class Mast Cell-Depleting Antibody Heading Toward Its Phase 3 Readout in Chronic Hives (September 17, 2026)
Barzolvolimab (CDX-0159) is an investigational Celldex antibody with a mechanism new to allergy: instead of blocking one mediator, it depletes mast cells by targeting the KIT (CD117) receptor they need to survive. In Phase 2 it deeply and durably cut hives scores in antihistamine-refractory chronic spontaneous urticaria and drove complete responses in cold urticaria and dermographism. Its replicate Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials - the largest program ever in antihistamine-refractory CSU, at 1,939 patients - report topline results in late 2026, with a BLA planned for 2027.
Amlitelimab: Sanofi's OX40L Antibody Bets on Fewer Shots and a Response That Grows Over Time (September 23, 2026)
Amlitelimab is Sanofi's anti-OX40L antibody for moderate-to-severe eczema - an upstream, non-T-cell-depleting approach dosed as few as four times a year, with a response that tends to deepen over months. Here's what the COAST 1, COAST 2 and SHORE Phase 3 data actually show, and where the open questions are.